|
AU686660B2
(en)
*
|
1993-08-11 |
1998-02-12 |
Jenner Technologies |
Prostatic cancer vaccine
|
|
US20010036928A1
(en)
*
|
1996-04-22 |
2001-11-01 |
Chamberlain Ronald S. |
Heterologous boosting immunizations
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
US7148035B1
(en)
|
1998-11-18 |
2006-12-12 |
Oxford Biomedica (Uk) Limited |
Polypeptide
|
|
EP2042598A1
(en)
*
|
1998-11-18 |
2009-04-01 |
Oxford Biomedica (UK) Limited |
5T4 tumour-associated antigen for use in tumour immunotherapy
|
|
AU774076C
(en)
*
|
1998-12-09 |
2005-04-14 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
A recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
EP1865065A1
(en)
*
|
1998-12-09 |
2007-12-12 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
A recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
WO2005035773A2
(en)
*
|
2003-10-08 |
2005-04-21 |
Sanofi Pasteur, Inc. |
Modified cea /b7 vector
|
|
ATE369895T1
(de)
*
|
2002-04-09 |
2007-09-15 |
Sanofi Pasteur Ltd |
Modifizierte cea nucleinsäure und expressionsvektoren
|
|
AU2004267117B2
(en)
*
|
2003-08-21 |
2011-01-20 |
Virax Development Pty Ltd |
Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer
|
|
ES2476990T3
(es)
|
2003-11-12 |
2014-07-15 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sistema para tratar y prevenir cáncer de mama
|
|
WO2005046622A2
(en)
|
2003-11-12 |
2005-05-26 |
Therion Biologics Corporation |
Custom vectors for treating and preventing pancreatic cancer
|
|
CA2744294A1
(en)
|
2009-01-13 |
2010-07-22 |
Transgene Sa |
Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
|
|
PT2382474E
(pt)
|
2009-01-20 |
2015-06-03 |
Transgene Sa |
Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica
|
|
BRPI1009892A2
(pt)
|
2009-03-24 |
2016-03-15 |
Transgène S A |
método ex-vivo para avaliar a eficácia de um tratamento em um paciente, e, kit para testar se um paciente está respondendo terapeuticamente a um método de tratamento compreendendo administração de uma composição imunogênica
|
|
BRPI1010512A2
(pt)
|
2009-04-17 |
2016-03-15 |
Transgène S A |
"método ex vivo para avaliar a eficácia de um tratamento envolvendo a administração de uma composição imunogênica a um paciente, e, uso de níveis de linfócitos t ativados (cd3 + cd69+) como um biomarcador"
|
|
EP2452194B1
(en)
|
2009-07-10 |
2015-11-11 |
Transgene SA |
Biomarker for selecting patients and related methods
|
|
AU2011285534B2
(en)
|
2010-08-06 |
2015-12-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Biomarkers for prostate cancer and methods for their detection
|
|
US9725494B2
(en)
*
|
2013-05-17 |
2017-08-08 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Soluble CD27 (sCD27) and the use thereof
|
|
JP6535337B2
(ja)
*
|
2013-11-05 |
2019-06-26 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法
|
|
ES2851451T3
(es)
|
2014-05-13 |
2021-09-07 |
Bavarian Nordic As |
Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
|
|
ES2833425T3
(es)
|
2014-07-16 |
2021-06-15 |
Roussy Inst Gustave |
Combinación de virus oncolítico con moduladores de punto de control inmunitario
|
|
CA2975432A1
(en)
|
2015-02-13 |
2016-08-18 |
Transgene Sa |
Immunotherapeutic vaccine and antibody combination therapy
|
|
DK3329016T3
(da)
|
2015-07-31 |
2022-01-10 |
Bavarian Nordic As |
Promotorer til forbedring af ekspression i poxvirus
|
|
US20190183870A1
(en)
|
2016-01-05 |
2019-06-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Combination of histone deacetylase inhibitor and immunotherapy
|
|
JP6902040B2
(ja)
|
2016-01-28 |
2021-07-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
免疫チェックポイント阻害剤の効力を増強する方法
|
|
WO2017136342A1
(en)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
|
|
CA3023022A1
(en)
|
2016-05-04 |
2017-11-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
|
AU2017336269B2
(en)
|
2016-09-28 |
2022-06-16 |
Bavarian Nordic A/S |
Compositions and methods for enhancing the stability of transgenes in poxviruses
|
|
WO2018069316A2
(en)
|
2016-10-10 |
2018-04-19 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
WO2018091680A1
(en)
|
2016-11-18 |
2018-05-24 |
Transgene Sa |
Cowpox-based oncolytic vectors
|
|
CA3045228C
(en)
|
2016-12-28 |
2024-01-02 |
Transgene Sa |
Oncolytic viruses and therapeutic molecules
|
|
BR112019021520A2
(pt)
|
2017-04-14 |
2020-08-04 |
Tollnine, Inc. |
oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
|
|
EP3624851A1
(en)
|
2017-05-15 |
2020-03-25 |
Janssen Vaccines & Prevention B.V. |
Stable virus-containing composition
|
|
CA3062549A1
(en)
|
2017-05-15 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Stable virus-containing composition
|
|
WO2019020543A1
(en)
|
2017-07-28 |
2019-01-31 |
Transgene Sa |
ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
|
|
IL272546B2
(en)
|
2017-08-24 |
2024-01-01 |
Bavarian Nordic As |
Combined therapy for the treatment of cancer with intravenous administration of recombinant MVA and antibody
|
|
CA3093093A1
(en)
|
2018-03-07 |
2019-09-12 |
Transgene |
Parapoxvirus vectors
|
|
WO2020011754A1
(en)
|
2018-07-09 |
2020-01-16 |
Transgene |
Chimeric vaccinia viruses
|
|
EP3847246A1
(en)
|
2018-09-06 |
2021-07-14 |
Bavarian Nordic A/S |
Storage improved poxvirus compositions
|
|
EP3976071A1
(en)
|
2019-05-29 |
2022-04-06 |
Université de Tours |
Toxoplasma platform for treating cancer
|
|
IL295759A
(en)
|
2020-02-28 |
2022-10-01 |
Tallac Therapeutics Inc |
Transglutaminase mediated coupling
|
|
JP7712284B2
(ja)
|
2020-03-12 |
2025-07-23 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
ポックスウイルスの安定性を改善する組成物
|
|
KR20250052416A
(ko)
|
2022-08-18 |
2025-04-18 |
트랜스진 |
키메라 폭스바이러스
|
|
WO2026041811A1
(en)
|
2024-08-23 |
2026-02-26 |
Transgene |
Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell
|